Vaccines
October is RSV Awareness Month
RSV is a respiratory virus that affects the lungs and breathing passages. Each year, approximately 177,000 adults 65 years and older are hospitalized in the US due to RSV. Our patient advocate, Irene, tells her story about what it was like having RSV.
Investors
We announced our quarter 1 2024 results on Wednesday, May 1st.
Press releases
- GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
- GSK announces positive topline data on co-administration of AREXVY and SHINGRIX
- Statement: Zantac (ranitidine) litigation – Russell and Hughes cases
Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSK Global links
Visit our Global site for additional features